Scipher Medicine, a biotechnology company specializing in network-based and AI-driven approaches to precision immunology, has entered into a strategic collaboration with Maxymune Therapeutics, a developer of novel therapeutics for immunological disorders. The partnership aims to integrate computational target prioritization with experimental immunology to accelerate the identification and validation of therapeutic targets in autoimmune and inflammatory diseases.
Under the agreement, Scipher will provide Maxymune access to its computational platform for target ranking and engagement optimization. Central to this effort is the generation of customized reports aligning Maxymune’s protein targets of interest with Scipher’s multi-omics disease network models. Scipher’s platform ranks targets based on predicted therapeutic efficacy, drawing on validation across more than 25 disease areas. This in-silico prioritization framework is intended to support decision-making regarding whether specific targets warrant continued preclinical investment.
Our platform is designed to de-risk therapeutic development by identifying the most promising targets through deep molecular network analysis. We are excited to support Maxymune’s innovative R&D programs with actionable data that aligns with our shared commitment to transforming the treatment landscape for immune-mediated diseases.
Dr. Reg Seeto, Chief Executive Officer of Scipher Medicine.
Our collaboration with Scipher combines Maxymune’s biological expertise with the power of Scipher’s AI platform to uncover unique insights into our target’s role in autoimmune diseases. By integrating these AI-driven discoveries with our rigorous in vitro and in vivo studies, we can triangulate findings, sharpen our discovery strategy, and move more rapidly toward transformative immunotherapies.
Tatjana Naranda, President and Chief Operating Officer of Maxymune Therapeutics.
The partnership highlights an increasing trend in drug discovery, the use of computational and AI-driven methods to enhance early-stage decision-making and improve the likelihood of clinical success. By combining in-silico target prioritization with experimental validation, the collaboration seeks to generate a more efficient pipeline for therapeutic development in immune-mediated diseases.